Frazier Life Sciences Management, L.P. Savara Inc Transaction History
Frazier Life Sciences Management, L.P.
- $1.59 Billion
- Q1 2025
A detailed history of Frazier Life Sciences Management, L.P. transactions in Savara Inc stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 11,462,301 shares of SVRA stock, worth $26.2 Million. This represents 2.0% of its overall portfolio holdings.
Number of Shares
11,462,301
Previous 8,660,379
32.35%
Holding current value
$26.2 Million
Previous $26.6 Million
19.42%
% of portfolio
2.0%
Previous 1.59%
Shares
4 transactions
Others Institutions Holding SVRA
# of Institutions
142Shares Held
162MCall Options Held
54.8KPut Options Held
4.1K-
Nea Management Company, LLC Timonium, MD24.5MShares$56 Million6.43% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA17.6MShares$40.3 Million16.36% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA12.4MShares$28.3 Million8.25% of portfolio
-
Vestal Point Capital, LP New York, NY11MShares$25.2 Million2.18% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.12MShares$18.6 Million0.0% of portfolio
About Savara Inc
- Ticker SVRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 114,043,000
- Market Cap $261M
- Description
- Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.